Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography
|Atrial Fibrillation Atrial Premature Complexes|
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Markers of Paroxysmal Atrial Fibrillation in Esophageal Holter Electrocardiography|
- Number atrial premature beats not conducted to the ventricles [ Time Frame: during analysis of the ECG ]
- Mean duration of the p-eso-wave [ Time Frame: during analysis of the esophageal ECG ]
- Mean duration of the left atrial wavefront [ Time Frame: during analysis of the esophageal ECG ]
- p-eso-wave-duration-dispersion [ Time Frame: during analysis of the esophageal ECG ]
- mean number of p-eso-wave-peaks [ Time Frame: during analysis of the esophageal ECG ]
- root mean square voltages of the last 20 ms of the p-eso-wave in the esophageal ECG [ Time Frame: during analysis of the esophageal ECG ]
|Study Start Date:||September 2011|
|Study Completion Date:||April 2015|
|Primary Completion Date:||March 2015 (Final data collection date for primary outcome measure)|
Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the "cases" group.
Controls: For every case patient, an age (+/- one year) and gender matched control person (n=30) without known paroxysmal atrial fibrillation will be included and matched to every case patient.
The fast and correct diagnosis of heart rhythm disorders is very important to reduce morbidity and mortality in cardiovascular patients. Atrial fibrillation is of special interest, because it is an important cause of devastating brain strokes. A significant number of strokes has a cardioembolic genesis due to paroxysmal atrial fibrillation which was not diagnosed early enough. Therefore, it is very important to detect atrial fibrillation as soon as possible. With oral anticoagulation an effective therapeutic option in available to prevent cardioembolisms.
In the clinical routine, mostly 24-hour or 7-day ECGs are made to look for cardiac arrhythmias. The use uf such devices is well established. Nevertheless, they have some side effects/limitations. Skin electrodes used for derivation of the ECG often cause skin irritation, sometimes leading to premature termination of the recording. Because of dryout of the contact gel (causes artifacts), small p-waves and especially also motion artifacts, triggered recording or semi-automatic analysis of the recording is problematic, but for longer recording times such a semi-automatic analysis would be helpful. As an alternative esophageal electrocardiography can be performed. Signal quality of the ECG recording (especially of the left atrium) is better than in the standard surface ECG because of the vicinity of the esophagus and the left atrium. The esophagus tolerates well foreign bodies as we know from long-term nasogastric intubation. Therefore use of the esophageal technique for long-term rhythm monitoring is an interesting and promising alternative to conventional surface Holter ECGs.
The diagnosis of paroxysmal atrial fibrillation (pAF) can only be made if an episode of atrial fibrillation occurs during the long-term ECG recording. Surrogate markers of pAF could identify a "population at risk" in which pAF has to be suspected although they show sinus rhythm during the time of recording. In surface ECG such markers have been suspected. The use of esophageal long-term electrocardiography with its better signal properties is a promising alternative to find such surrogate markers for risk stratification.
Identification and characterization of surrogate markers indicative for pAF in patients with sinus rhythm at the time of recording.
A total of 60 patients will be included to identify and characterize surrogate markers for pAF. Cases with known pAF will consecutively be recruited from the cardiology ward and the cardiological ambulatory. After inclusion, an age (+/- one year) and gender adjusted control person without known pAF (negative 7-day ECG within the previous 365 days before study inclusion) will be matched to every patient. Cases and controls will receive a simultaneous 24-hour esophageal electrocardiography and standard surface electrocardiography. Controls without negative 7-day ECG within the past year will have to wear the surface ECG recorder for additional 6 days (total surface ECG recording of 7 days). In the case that paroxysmal atrial fibrillation is detected for the very first time during the study, patients will be allocated to the "case" group.
Additionally, in all patients LA diameter parasternal will be measured echocardiographically.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01436344
|Department of Cardiology, Bern University Hospital|
|Bern, Switzerland, 3010 Bern|
|Principal Investigator:||Rolf Vogel, MD, PhD||Bern University Hospital|
|Principal Investigator:||Andreas D Haeberlin, MD||Bern University Hospital|